PrEPVacc study reports that experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition

Today, the EDCTP-funded PrEPVacc HIV prevention study has announced that it stopped its experimental vaccine regimens as there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition. The study has conducted experimental vaccine regimens and a new form of oral pre-exposure prophylaxis (PrEP) in 1,500 participants from East and Southern Africa. The decision to stop vaccinations immediately was based on the recommendations of its independent data monitoring committee. The committee has recommended that the oral PrEP component of the study continue to completion.

EDCTP commends the PrEPVacc consortium for their excellent management of this complex trial. We continue to work with the consortium to support the study in generating and analysing the data for future vaccine development. We thank all the trial participants for their cooperation and support to this study.

Read the full statement from the PrEPVAcc study team.